In a finding that highlights ways to optimize the efficacy of antibody-based therapeutics and vaccines, the activity of potent HIV-1-neutralizing antibodies has been confirmed to depend on cellular binding to the antibodies' Fc regions.
This is a preview of subscription content, log in via an institution to check access.
References
Koff, W. C. et al. Science 340, 1232910 (2013).
Burton, D. R. et al. Cell Host Microbe 12, 396–407 (2012).
Mascola, J. R. & Montefiori, D. C. Annu. Rev. Immunol. 28, 413–444 (2010).
Bournazos, S. et al. Cell 158, 1243–1253 (2014).
Hessell, A. J. et al. Nature 449, 101–104 (2007).
Barouch, D. H. et al. Nature 503, 224–228 (2013).
Klein, F. et al. Nature 492, 118–122 (2012).
Trkola, A. et al. Nature Med. 11, 615–622 (2005).
Poignard, P. et al. Immunity 10, 431–438 (1999).
Ko, S.-Y. et al. Nature http://dx.doi.org/10.1038/nature13612 (2014).
Abela, I. A. et al. PLoS Pathog. 8, e1002634 (2012).
Ackerman, M. E., Dugast, A. S. & Alter, G. Annu. Rev. Med. 63, 113–130 (2012).
Ackerman, M. E. & Alter, G. Curr. HIV Res. 11, 365–377 (2013).
Huber, M. et al. PLoS Med. 3, e441 (2006).
Burton, D. R. et al. Proc. Natl Acad. Sci. USA 108, 11181–11186 (2011).
Platt, E. J., Gomes, M. M. & Kabat, D. Proc. Natl Acad. Sci. USA 109, 7829–7834 (2012).
Ruprecht, C. R. et al. J. Exp. Med. 208, 439–454 (2011).
Yasmeen, A. et al. Retrovirology 11, 41 (2014).
Magnus, C., Rusert, P., Bonhoeffer, S., Trkola, A. & Regoes, R. R. J. Virol. 83, 1523–1531 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trkola, A. Potency needs constancy. Nature 514, 442–443 (2014). https://doi.org/10.1038/514442a
Published:
Issue Date:
DOI: https://doi.org/10.1038/514442a
- Springer Nature Limited